Diyong Xu bought $15.0M of Q32 Bio (QTTB)
Executed May 28, disclosed Jun 2, 4 days later.
Over the 21 trading sessions from the disclosed entry session (Jun 1), the stock returned +17.7% (delay-adjusted); from the execution session (May 28), +14.3%. Derived: entry at the session's open, exit at the close 20 sessions later.
Diyong Xu (Director) filed 1 Form 4 report in the trailing twelve months (1 purchase, 0 sales), most often in Q32 Bio Inc. (QTTB). Across 1 priced purchase filing, the average 21-session return was +14.3% from execution and +17.7% from disclosure (delay-adjusted; derived). The largest single filing was $15.0M of QTTB (1,875,000 sh across 2 lots, as filed), executed May 28.
Healthcare · Q32 Bio Inc., a clinical-stage biotechnology company, develops novel biologics to restore healthy immune balance in patients with alopecia…
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→